Sarepta Therapeutics, Inc. (SRPT) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is held by 315 institutional firms.

• The collective stake of institutional investors in Sarepta Therapeutics moved to 91.5% in September 2025, a shift up from the 88.5% reported for June 2025.
• The company experienced a 18.89% quarterly change in institutional shares held, alongside a decrease of 30.92% in total owners annually.
• The latest 13F cycle for Sarepta Therapeutics reveals that of 315 total investors, 166 funds grew their exposure, whereas 111 reduced theirs and 38 made no changes.
• The aggregate institutional position in Sarepta Therapeutics now stands at 89.38Mn shares as of September 2025, after investors increased their holdings (up by 14.20Mn shares quarter on quarter which is up 50.24K shares year over year).
• BlackRock, Inc.'s holding of 13.20Mn shares as of September 30, 2025 makes it the primary institutional investor in Sarepta Therapeutics, owning 13.51% of the stock.
• Among the most significant buyers of Sarepta Therapeutics during September 2025 were RENAISSANCE TECHNOLOGIES LLC (2.03Mn), VANGUARD GROUP INC (1.66Mn), UBS Group AG (1.49Mn), FIRST TRUST ADVISORS LP (1.31Mn), AQR CAPITAL MANAGEMENT LLC (1.28Mn).
• Leading sellers of Sarepta Therapeutics stock in September 2025 included D. E. Shaw & Co., Inc. (2.47Mn), JANE STREET GROUP, LLC (1.40Mn), Assenagon Asset Management S.A. (838.46K), Y-Intercept (Hong Kong) Ltd (791.45K), MILLENNIUM MANAGEMENT LLC (778.00K).
• The top 10 institutional holders of Sarepta Therapeutics for the quarter ending September 2025 included BlackRock, Inc. (13.20Mn), VANGUARD GROUP INC (10.82Mn), STATE STREET CORP (5.30Mn), Erste Asset Management GmbH (2.69Mn), RENAISSANCE TECHNOLOGIES LLC (2.65Mn), TWO SIGMA INVESTMENTS, LP (2.14Mn), D. E. Shaw & Co., Inc. (2.01Mn), UBS Group AG (1.99Mn), Aberdeen Group plc (1.98Mn), TWO SIGMA ADVISERS, LP (1.96Mn).